Home > Healthcare > Pharmaceuticals > Finished Drug Form > Carglumic Acid Market

Carglumic Acid Market Size

  • Report ID: GMI8505
  • Published Date: Mar 2024
  • Report Format: PDF

Carglumic Acid Market Size

Carglumic Acid Market size was valued at around USD 148.6 million in 2023 and is expected to reach around USD 280 million by 2032 at a CAGR of 7.1% during the forecast period. The growing prevalence of metabolic diseases is anticipated to be among primary factor propelling the growth of the market.

 

The rising incidences of metabolic diseases globally, including metabolic syndrome, type 2 diabetes mellitus, hypertension, and non-alcoholic fatty liver disease (NAFLD) are a growing concern, with significant increases observed in prevalence rates over the years. According to the Centers for Disease Control and Prevention (CDC), nearly half of adults in the U.S. have hypertension, affecting an estimated 119.9 million adults.
 

Additionally, the World Health Organization (WHO) emphasizes the importance of early diagnosis through regular check-ups and blood tests to prevent the worst effects of type 2 diabetes. This rise in the prevalence of such metabolic conditions is anticipated as a key factor contributing to the growth of the market.
 

Carglumic acid is a medication used for the treatment of hyperammonemia, a condition characterized by elevated levels of ammonia in the blood. Hyperammonemia can be caused by various metabolic disorders, including urea cycle disorders. Carglumic acid works by promoting the excretion of ammonia in the urine, thereby reducing its concentration in the blood.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global carglumic acid industry was valued at around USD 148.6 million in 2023 and is expected to reach around USD 280 million by 2032 at a CAGR of 7.1%, driven by the growing prevalence of metabolic diseases.

The hospital pharmacies segment accounted for a revenue of around USD 77 million in 2023, as they handle the distribution of medications for complex conditions such as hyperammonemia, ensuring that patients receive the necessary treatment.

North America carglumic acid market accounted for USD 60.4 million in 2023, attributed to the rising healthcare expenditure in the region, associated with a growing emphasis on specialty care and rare diseases treatment.

Apothecon Pharmaceuticals Pvt. Ltd., Biophore India Pharmaceuticals Pvt Ltd., Dipharma Francis S.r.l., Eton Pharmaceuticals, KAVYA PHARMA, MANUS AKTTEVA BIOPHARMA LLP, Merck KGaA, NOVITIUM PHARMA LLC, NURAY CHEMICALS, Recordati Rare Diseases Inc., and Suven Life Sciences Limited.

Carglumic Acid Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 136
  • Countries covered: 22
  • Pages: 100
 Download Free Sample